Parstatin, a novel protease-activated receptor 1-derived inhibitor of angiogenesis

Molecular Interventions

Volumn 9, Issue 4, 2009, Pages 168-170

  Duncan, Michael B ^a   Kalluri, Raghu ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; PARSTATIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; CELL PROLIFERATION; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; HEART MUSCLE ISCHEMIA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; REVIEW;

ANGIOGENESIS INHIBITORS; ANIMALS; DRUG THERAPY; GENE EXPRESSION; HUMANS; PEPTIDE FRAGMENTS; RECEPTOR, PAR-1;

EID: 69749111076     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.9.4.4     Document Type: Review

References (28)

1. Folkman, J. Angiogenesis. Annu. Rev. Med. 57, 1-18 (2006).
2. Cao, Y. Tumor angiogenesis and molecular targets for therapy. Front. Biosci. 14, 3962-3973 (2009).
3. Fukumura, D. and Jain, R.K. Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization. Microvasc. Res. 74, 72-84 (2007).
4. Hanahan, D. and Weinberg, R.A. The hallmarks of cancer. Cell 100, 57-70 (2000).
5. Ciulla, T.A. and Rosenfeld, P.J. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr. Opin. Ophthalmol. 20, 158-165 (2009).
6. Hanahan, D. and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364 (1996). (Pubitemid 26272076)
7. Ferrara, N., Mass, R.D., Campa, C., and Kim, R. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu. Rev. Med. 58, 491-504 (2007).
8. Folkman, J. Is angiogenesis an organizing principle in biology and medicine? J. Pediatr. Surg. 42, 1-11 (2007).
9. Ribatti, D. Endogenous inhibitors of angiogenesis: A historical review. Leuk. Res. 33, 638-644 (2009).
10. Maeshima, Y., Colorado, P.C., Torre, A., et al. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J. Biol. Chem. 275, 21340-21348 (2000).
11. O'Reilly, M.S., Boehm, T., Shing, Y. et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285 (1997). (Pubitemid 28015876)
12. Mongiat, M., Sweeney, S.M., San Antonio, J.D., Fu, J., and Iozzo, R.V. Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J. Biol. Chem. 278, 4238-4249 (2003).
13. O'Reilly, M.S., Holmgren, L., Shing, Y. et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328 (1994). (Pubitemid 24324921)
14. O'Reilly, M.S., Pirie-Shepherd, S., Lane, W.S., and Folkman, J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285, 1926-1928 (1999).
15. Wakasugi, K., Slike, B.M., Hood, J., Otani, A., Ewalt, K.L., Friedlander, M., Cheresh, D.A., and Schimmel, P. A human aminoacyl-tRNA synthetase as a regulator of angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 99, 173-177 (2002).
16. Zania, P., Gourni, D., Aplin, A.C., Nicosia, R.F., Flordellis, C.S., Maragoudakis, M.E., and Tsopanoglou, N.E. Parstatin, the cleaved peptide on proteinase-activated receptor 1 activation, is a potent inhibitor of angiogenesis. J. Pharmacol. Exp. Ther. 328, 378-389 (2009).
17. Coughlin, S.R. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J. Thromb. Haemost. 3, 1800-1814 (2005).
18. Griffin, C.T., Srinivasan, Y., Zheng, Y.W., Huang, W., and Coughlin, S.R. A role for thrombin receptor signaling in endothelial cells during embryonic development. Science 293, 1666-1670 (2001). (Pubitemid 32807847)
19. Ma, L., Perini, R., McKnight, W., Dicay, M., Klein, A., Hollenberg, M.D., and Wallace, J.L. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc. Natl. Acad. Sci. U.S.A. 102, 216-220 (2005).
20. Yin, Y.J., Salah, Z., Maoz, M., Ram, S.C., Ochayon, S., Neufeld, G., Katzav, S., and Bar-Shavit, R. Oncogenic transformation induces tumor angiogenesis: A role for PAR1 activation. FASEB J. 17, 163-174 (2003). (Pubitemid 36164386)
21. Boire, A., Covic, L., Agarwal, A., Jacques, S., Sherifi, S., and Kuliopulos, A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120, 303-313 (2005). (Pubitemid 40222426)
22. Ramachandran, R. and Hollenberg, M.D. Proteinases and signalling: Pathophysiological and therapeutic implications via PARs and more. Br. J. Pharmacol. 153 Suppl 1, S263-S282 (2008).
23. Rudroff, C., Seibold, S., Kaufmann, R. et al. Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro. Clin. Exp. Metastasis 19, 181-189 (2002).
24. Ossovskaya, V.S. and Bunnett, N.W. Protease-activated receptors: Contribution to physiology and disease. Physiol. Rev. 84, 579-621 (2004).
25. Russo, A., Soh, U.J., and Trejo, J. Proteases display biased agonism at protease-activated receptors: Location matters! Mol. Interv. 9, 87-96 (2009).
26. Chen, J., Ishii, M., Wang, L., Ishii, K., and Coughlin, S.R. Thrombin receptor activation. Confirmation of the intramolecular tethered liganding hypothesis and discovery of an alternative intermolecular liganding mode. J. Biol. Chem. 269, 16041-16045 (1994).
27. Vu, T.K., Hung, D.T., Wheaton, V.I., and Coughlin, S.R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64, 1057-1068 (1991).
28. Strande, J.L., Widlansky, M.E., Tsopanoglou, N.E., Su, J., Wang, J., Hsu, A., Routhu, K.V., and Baker, J.E. Parstatin: A cryptic peptide involved in cardioprotection after ischaemia and reperfusion injury. Cardiovasc. Res. 83, 325-334. Epub Apr 20 (2009).